Publications by authors named "Joan Mackell"

Claim this Profile
S
Speed of Improvement in Symptoms of Depression With Desvenlafaxine 50 mg and 100 mg Compared With Placebo in Patients With Major Depressive Disorder.
Martin A Katzman, Andrew A Nierenberg, Dalia B Wajsbrot, Ellen Meier, Rita Prieto, Joan Mackell

J Clin Psychopharmacol· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of desvenlafaxine 50 mg and 100 mg on energy and lassitude in patients with major depressive disorder: A pooled analysis.
Raymond W Lam, Dalia B Wajsbrot, Ellen Meier, Elizabeth Pappadopulos, Joan A Mackell

J Psychopharmacol· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of metabolic syndrome and thyroid hormone on efficacy of desvenlafaxine 50 and 100 mg/d in major depressive disorder.
Roger S McIntyre, Rana Fayyad, Joan A Mackell, Matthieu Boucher

Curr Med Res Opin· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An integrated analysis of the efficacy and safety of desvenlafaxine in the treatment of major depressive disorder.
José L Carrasco, Susan G Kornstein, Roger S McIntyre, Rana Fayyad, Rita Prieto, Joan Mackell

Int Clin Psychopharmacol· May 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of donepezil 23 mg on Severe Impairment Battery domains in patients with moderate to severe Alzheimer's disease: evaluating the impact of baseline severity.
Steven Ferris, Jeffrey Cummings, Daniel Christensen, Rachelle Doody, Martin Farlow, Joan Mackell

Alzheimers Res Ther· August 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluating the cognitive effects of donepezil 23 mg/d in moderate and severe Alzheimer's disease: analysis of effects of baseline features on treatment response.
Marwan Sabbagh, Jeffrey Cummings, Daniel Christensen, Rachelle Doody, Martin Farlow, Joan Mackell

BMC Geriatr· June 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of donepezil 23 mg versus donepezil 10 mg for moderate-to-severe Alzheimer's disease: a subgroup analysis in patients already taking or not taking concomitant memantine.
Rachelle S Doody, David S Geldmacher, Martin R Farlow, Yijun Sun, Margaret Moline, Joan Mackell

Dement Geriatr Cogn Disord· November 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Subgroup analysis of US and non-US patients in a global study of high-dose donepezil (23 mg) in moderate and severe Alzheimer's disease.
Stephen Salloway, Jacobo Mintzer, Jeffrey L Cummings, David Geldmacher, Yijun Sun, Joan Mackell

Am J Alzheimers Dis Other Demen· September 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term safety and tolerability of donepezil 23 mg in patients with moderate to severe Alzheimer's disease.
Pierre Tariot, Steven Salloway, Jane Yardley, Joan Mackell, Margaret Moline

BMC Res Notes· June 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Collaborative research between academia and industry using a large clinical trial database: a case study in Alzheimer's disease.
Roy Jones, David Wilkinson, Oscar L Lopez, Jeffrey Cummings, Gunhild Waldemar, Joan Mackell

Trials· October 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Analyzing the impact of 23 mg/day donepezil on language dysfunction in moderate to severe Alzheimer's disease.
Steven H Ferris, Frederick A Schmitt, Judith Saxton, Sharon Richardson, Joan Mackell

Alzheimers Res Ther· June 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of donepezil on emergence of apathy in mild to moderate Alzheimer's disease.
Gunhild Waldemar, Serge Gauthier, Roy Jones, David Wilkinson, Jeffrey Cummings, Joan Mackell

Int J Geriatr Psychiatry· February 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of donepezil on cognition in severe Alzheimer's disease: a pooled data analysis.
Jeffrey Cummings, Roy Jones, David Wilkinson, Oscar Lopez, Serge Gauthier, Joan Mackell

J Alzheimers Dis· January 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of donepezil in patients with Alzheimer's disease in assisted living facilities.
Adam Rosenblatt, Jeff Gao, Joan Mackell, Sharon Richardson

Am J Alzheimers Dis Other Demen· September 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effectiveness and safety of donepezil in Hispanic patients with Alzheimer's disease: a 12-week open-label study.
Oscar L Lopez, Joan A Mackell, Yijun Sun, Laurent M Kassalow, Yikang Xu

J Natl Med Assoc· November 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Behavioral effects of current Alzheimer's disease treatments: a descriptive review.
Jeffrey L Cummings, Joan Mackell, Daniel Kaufer

Alzheimers Dement· January 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reduced mortality rates after intensive statin therapy in managed-care patients.
Dan Fintel, Amie Joyce, Joan Mackell, Jennifer Graff, Erik Kuntze

Value Health· May 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Relationship between preventative physical health care and mental health in individuals with schizophrenia: a survey of caregivers.
Joan A Mackell, David J Harrison, Diana D McDonnell

Ment Health Serv Res· December 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reliability of monitoring the clinical dementia rating in multicenter clinical trials.
Kimberly A Schafer, Rochelle E Tractenberg, Mary Sano, Joan A Mackell, Ronald G Thomas

Alzheimer Dis Assoc Disord· April 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Economic consequences of the adverse reactions related with antipsychotics: an economic model comparing tolerability of ziprasidone, olanzapine, risperidone, and haloperidol in Spain.
Julio Bobes, Fernando Cañas, Javier Rejas, Joan Mackell

Prog Neuropsychopharmacol Biol Psychiatry· December 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Obesity as a risk factor for antipsychotic noncompliance.
Peter J Weiden, Joan A Mackell, Diana D McDonnell

Schizophr Res· January 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment adherence associated with conventional and atypical antipsychotics in a large state Medicaid program.
Joseph Menzin, Luke Boulanger, Mark Friedman, Joan Mackell, John R Lloyd

Psychiatr Serv· May 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The impact of weight gain on quality of life among persons with schizophrenia.
David B Allison, Joan A Mackell, Diana D McDonnell

Psychiatr Serv· April 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The economic impact of migraine: an analysis of direct and indirect costs.
John Edmeads, Joan A Mackell

Headache· June 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis